About Alzheon
Alzheon is a clinical-stage biopharmaceutical company with a Phase 3 program in Alzheimer’s disease and a discovery platform of small molecules for the treatment of neurodegenerative disorders. We are developing these disease modifying treatments by leveraging our expertise in inhibiting protein misfolding and aggregation.
Our Experienced Team
We are a passionate and highly experienced team of neuroscientists, pharmacologists, clinicians, drug developers and business leaders with a deep understanding of neurological and psychiatric disorders and a track record of successfully developing products to treat these diseases. We believe our team positions us to become a leading company developing disease modifying therapies for the treatment of neurodegenerative disorders.
Valiltramiprosate/ALZ-801 for Alzheimer’s disease
Valiltramiprosate is an investigational small molecule inhibitor of the formation of neurotoxic amyloid oligomers. In October 2017, the FDA designated valiltramiprosate as a Fast Track development program for the investigation of Alzheimer’s disease. Phase 3 trial for valiltramiprosate in APOE4/4 homozygous patients with Early Alzheimer’s launched in 2021.
Financial Conflict of Interest (FCOI) Policy
In compliance with federal regulations, Alzheon Inc. requires Investigators and Key Personnel participating in Public Health System (PHS) sponsored research to disclose Significant Financial Interests (SFI) that could reasonably bias the design, conduct, or reporting of the project.
Please click below to download the full copy of the Alzheon Inc. Financial Conflict of Interest Policy.
For more information, visit the following links:
42 CFR Part 50 https://grants.nih.gov/grants/policy/coi/fcoi_final_rule.pdf
NIH FCOI https://grants.nih.gov/grants/policy/coi/index.htm
NIH FCOI FAQs https://grants.nih.gov/grants/policy/coi/coi_faqs.htm
NIH FCOI Tutorial https://grants.nih.gov/grants/policy/coi/tutorial2011/fcoi.htm
Point of Contact:
If you have questions about the Financial Conflict of Interest Policy or existing disclosures, please contact the designated Institutional Official at ap@alzheon.com.